Selank: Research Overview

The short version

Selank is a synthetic heptapeptide built from tuftsin, a naturally occurring four-amino-acid fragment of an antibody (IgG) that the immune system produces. Researchers extended tuftsin with an extra three-amino-acid tail — the same Pro-Gly-Pro stabilizing strategy used with Semax — to slow its breakdown and prolong its activity.

Selank has been studied mainly for anxiolytic (anxiety-reducing) effects, through mechanisms distinct from benzodiazepine sedatives: it appears to modulate GABA receptors and to inhibit enzymes that break down the body's own opioid-like peptides. It is registered in Russia as an anxiolytic; it has no FDA or EMA approval and is sold in the US only as a research chemical.

As with the other two peptides on this desk, a meaningful share of the research on Selank used intranasal administration. This page reports what those studies found — never a routine for a person.

What it is

Selank is the synthetic heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro — the endogenous immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg, itself a fragment of the IgG heavy chain) extended at the C-terminus with the same Pro-Gly-Pro tripeptide used to stabilize Semax, improving metabolic stability and slowing enzymatic degradation. It is also referenced in the literature as TP-7 or the Selank heptapeptide.

How it works

Selank's anxiolytic and nootropic effects are attributed to two main, non-benzodiazepine mechanisms. First, it behaves as a positive allosteric modulator of GABA receptors — it enhances GABA's own binding rather than acting at the same site as a benzodiazepine, and it shifts the expression of GABA-pathway genes toward a pattern that correlates with GABA's own effects ^[8]. Second, it inhibits enkephalin-degrading enzymes, stabilizing the body's own opioid-like peptides and engaging the endogenous opioid/anti-anxiety system.

Beyond those two axes, Selank alters serotonin and dopamine turnover and modulates BDNF expression in the rodent hippocampus, and it shifts the Th1/Th2 balance of the immune system — an immunomodulatory profile inherited from its tuftsin origin and distinct from classical anxiolytics.

What the research shows

GABA-receptor modulation. A review of Selank's molecular pharmacology establishes its anxiolytic activity as centered on positive allosteric modulation of GABA-receptor binding, with subtype-selective, concentration-dependent effects that differ mechanistically from benzodiazepines and that can, in binding assays, block the modulatory activity of diazepam and olanzapine — indicating distinct but overlapping binding sites ^[6].

Combination with diazepam. In a rat model of unpredictable chronic mild stress, the combination of diazepam with Selank was the most effective intervention tested for reducing anxiety-like behavior, restoring behavior toward pre-stress levels and supporting a genuine GABAergic interaction between the two agents ^[7].

Gene expression. Selank administration changed the expression of 45 genes involved in GABAergic neurotransmission in rat frontal cortex one hour after dosing, and 22 genes at three hours, with a positive correlation between Selank-induced and GABA-induced expression changes ^[8].

Intranasal dosing and BDNF. Intranasal administration of Selank increased BDNF expression in the rat hippocampus in vivo, linking the peptide to neuroplasticity-related signaling and demonstrating that the intranasal route reaches hippocampal tissue in this model ^[9].

Human immunomodulation. In patients with anxiety-asthenic disorders, Selank altered the Th1/Th2 cytokine balance and modulated IL-6 expression in serum — one of the few human studies in the Selank literature, and the basis for describing Selank as an immunomodulator alongside its anxiolytic action ^[10].

Reported effects, cautions & safety

Reported benefits (anecdotal, not clinical evidence): The most consistent community report is a softening of background anxiety without sedation — people describe the "edge" coming off while the mind stays clear, often contrasted explicitly with benzodiazepines or SSRIs. Many report reduced situational and social anxiety ahead of stressful events, a fast (roughly 20-40 minute) onset when used intranasally, steadier focus, and a gradual mood lift over one to two weeks of regular use. A notable minority report little or no effect at all.

Reported adverse effects (anecdotal, not clinical evidence): The most common complaint tied to the intranasal route itself is mild nasal dryness, burning, or sneezing from the spray or drops. A minority describe mild tiredness or over-calm, occasional headache, or a short single-dose duration that prompts redosing through the day. Community accounts widely note the absence of the tolerance or withdrawal pattern seen with benzodiazepines, though this rests on short-term, anecdotal experience rather than long controlled trials.

Cited cautions from the literature:

• Unregulated sourcing. Material sold outside Russia is a research chemical, not a pharmaceutical-grade product; identity, purity, and content vary by supplier.
• Limited long-term human data. Human evidence is largely confined to small Russian clinical studies over courses of a few weeks; short, single-region trials cannot speak to chronic or repeated use over months or years ^[6][7][10].
• Interaction unknowns. Selank's GABAergic, endogenous-opioid, monoaminergic, and immune activity gives it several axes on which it could interact with sedatives, opioids, or serotonergic and dopaminergic medications — a rat study specifically found the diazepam combination the most effective anxiolytic tested, underlining the pharmacological overlap ^[7].
• Immune-signaling activity is a distinct unknown. As a tuftsin analogue, Selank shifts Th1/Th2 cytokine balance in humans ^[10]; the downstream consequences of nudging immune signaling in people with autoimmune conditions or on immune-modulating medications are not characterized.
• Not a substitute for evaluation of persistent anxiety. Even the Russian clinical studies were conducted under medical supervision in diagnosed patients, not as unsupervised self-experimentation ^[10].

Where it fits in Cognitive & Nootropic research

Selank occupies the anxiety and mood-regulation slot on this desk, distinguished from Semax by its GABAergic mechanism and from DSIP by having a far more characterized — if still single-region — evidence base. Its own intranasal BDNF study ^[9] sits alongside Semax's and DSIP's intranasal work as one of the three data points behind this site's nose-to-brain framing. See the comparison page for how the three peptides line up side by side.